Leigh U. Horsfall
YOU?
Author Swipe
View article: Serum CC-Chemokine Ligand 2 Is Associated with Visceral Adiposity but Not Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease
Serum CC-Chemokine Ligand 2 Is Associated with Visceral Adiposity but Not Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease Open
Background: Non-alcoholic fatty liver disease (NAFLD) is caused by ectopic fat accumulation in the liver as a consequence of metabolic perturbations associated with obesity, type 2 diabetes, dyslipidemia, and insulin resistance. People wit…
View article: Medication Discrepancies and Regimen Complexity in Decompensated Cirrhosis: Implications for Medication Safety
Medication Discrepancies and Regimen Complexity in Decompensated Cirrhosis: Implications for Medication Safety Open
Discrepancies between the medicines consumed by patients and those documented in the medical record can affect medication safety. We aimed to characterize medication discrepancies and medication regimen complexity over time in a cohort of …
View article: Predicting Liver‐Related Outcomes in People With Nonalcoholic Fatty Liver Disease: The Prognostic Value of Noninvasive Fibrosis Tests
Predicting Liver‐Related Outcomes in People With Nonalcoholic Fatty Liver Disease: The Prognostic Value of Noninvasive Fibrosis Tests Open
It remains unclear whether screening for advanced fibrosis in the community can identify the subgroup of people with nonalcoholic fatty liver disease (NAFLD) at higher risk for development of liver‐related complications. We aimed to determ…
View article: Towards collaborative management of non‐alcoholic fatty liver disease: a ‘real‐world’ pathway for fibrosis risk assessment in primary care
Towards collaborative management of non‐alcoholic fatty liver disease: a ‘real‐world’ pathway for fibrosis risk assessment in primary care Open
Background The optimal strategy to support primary care practitioners (PCP) to assess fibrosis severity in non‐alcoholic fatty liver disease (NAFLD) and thereby make appropriate management decisions remains unclear. Aims To examine the fea…
View article: The Patient’s Perspective in Cirrhosis: Unmet Supportive Care Needs Differ by Disease Severity, Etiology, and Age
The Patient’s Perspective in Cirrhosis: Unmet Supportive Care Needs Differ by Disease Severity, Etiology, and Age Open
Patients with cirrhosis have significant physical, psychological, and practical needs. We documented patients’ perceived need for support with these issues and the differences with increasing liver disease severity, etiology, and age. Usin…
View article: Serum matrix metalloproteinase 7 (MMP7) is a biomarker of fibrosis in patients with non-alcoholic fatty liver disease
Serum matrix metalloproteinase 7 (MMP7) is a biomarker of fibrosis in patients with non-alcoholic fatty liver disease Open
Non-alcoholic fatty liver disease (NAFLD) affects 25% of the adult population globally. Since liver fibrosis is the most important predictor of liver-related complications in patients with NAFLD, identification of patients with advanced fi…
View article: Detecting non-alcoholic fatty liver disease and risk factors in health databases: accuracy and limitations of the ICD-10-AM
Detecting non-alcoholic fatty liver disease and risk factors in health databases: accuracy and limitations of the ICD-10-AM Open
Objective The prevalence of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) cirrhosis is often underestimated in healthcare and administrative databases that define disease burden using International Clas…
View article: Assessment of health‐related quality of life and health utilities in Australian patients with cirrhosis
Assessment of health‐related quality of life and health utilities in Australian patients with cirrhosis Open
Background and Aim Health‐related quality‐of‐life measurements are important to understand lived experiences of patients who have cirrhosis. These measures also inform economic evaluations by modelling quality‐adjusted life years (QALYs). …
View article: Effectiveness of patient‐oriented education and medication management intervention in people with decompensated cirrhosis
Effectiveness of patient‐oriented education and medication management intervention in people with decompensated cirrhosis Open
People with chronic disease often have poor comprehension of their disease and medications, which can negatively affect health outcomes. In a randomised‐controlled trial, we found that patients with decompensated cirrhosis who received a p…
View article: ICD-10-AM codes for cirrhosis and related complications: key performance considerations for population and healthcare studies
ICD-10-AM codes for cirrhosis and related complications: key performance considerations for population and healthcare studies Open
Objective The utility of International Classification of Diseases (ICD) codes relies on the accuracy of clinical reporting and administrative coding, which may be influenced by country-specific codes and coding rules. This study explores th…
View article: <p>Development and Evaluation of the Supportive Needs Assessment Tool for Cirrhosis (SNAC)</p>
Development and Evaluation of the Supportive Needs Assessment Tool for Cirrhosis (SNAC) Open
These data provide initial evidence for the validity and reliability of the SNAC, an instrument designed to measure type and amount of perceived unmet practical and psychological needs of people diagnosed with cirrhosis.
View article: Nonalcoholic Fatty Liver Disease: Interface Between Primary Care and Hepatology Clinics
Nonalcoholic Fatty Liver Disease: Interface Between Primary Care and Hepatology Clinics Open
Primary care physicians (PCPs) have the primary role in the diagnosis and management of nonalcoholic fatty liver disease (NAFLD), and in selecting patients for referral to a hepatologist for further evaluation. This study aimed to characte…
View article: Medication‐Related Problems in Outpatients With Decompensated Cirrhosis: Opportunities for Harm Prevention
Medication‐Related Problems in Outpatients With Decompensated Cirrhosis: Opportunities for Harm Prevention Open
People with decompensated cirrhosis are often prescribed a complex regimen of therapeutic and prophylactic medications. In other chronic diseases, polypharmacy increases the risk of medication misadventure and medication‐related problems (…
View article: A Pragmatic Approach Identifies a High Rate of Nonalcoholic Fatty Liver Disease With Advanced Fibrosis in Diabetes Clinics and At‐Risk Populations in Primary Care
A Pragmatic Approach Identifies a High Rate of Nonalcoholic Fatty Liver Disease With Advanced Fibrosis in Diabetes Clinics and At‐Risk Populations in Primary Care Open
Noninvasive serum biomarkers (nonalcoholic fatty liver disease fibrosis score [NFS], fibrosis 4 score [FIB‐4], or enhanced liver fibrosis [ELF] test) are recommended as first‐line tools to determine the risk of advanced fibrosis in nonalco…
View article: Hepatic expression profiling identifies steatosis-independent and steatosis-driven advanced fibrosis genes
Hepatic expression profiling identifies steatosis-independent and steatosis-driven advanced fibrosis genes Open
Chronic liver disease (CLD) is associated with tissue-destructive fibrosis. Considering that common mechanisms drive fibrosis across etiologies, and that steatosis is an important cofactor for pathology, we performed RNA sequencing on live…
View article: Medication beliefs predict medication adherence in ambulatory patients with decompensated cirrhosis
Medication beliefs predict medication adherence in ambulatory patients with decompensated cirrhosis Open
The association between "Low" adherence and patients having strong concerns or doubting the necessity or helpfulness of their medications should be explored further given the clinical relevance.
View article: Patient-oriented education and medication management intervention for people with decompensated cirrhosis: study protocol for a randomized controlled trial
Patient-oriented education and medication management intervention for people with decompensated cirrhosis: study protocol for a randomized controlled trial Open
Australian and New Zealand Clinical Trial Registry identifier: ACTRN12616000780459 . Registered on 15 June 2016.
View article: Multimorbidity and polypharmacy in diabetic patients with NAFLD
Multimorbidity and polypharmacy in diabetic patients with NAFLD Open
An observational study describing the number and type of chronic conditions and medications taken by diabetic patients with NAFLD and identifying characteristics that may impact liver disease severity or clinical management.Adults with typ…
View article: Exploratory study into the unmet supportive needs of people diagnosed with cirrhosis in Queensland, Australia
Exploratory study into the unmet supportive needs of people diagnosed with cirrhosis in Queensland, Australia Open
Background Many patients with cirrhosis follow complex medication and dietary regimens, and those with decompensated cirrhosis suffer debilitating complications. These factors impact activities of daily living and quality of life. Aims To …
View article: Alcohol Consumption in Diabetic Patients with Nonalcoholic Fatty Liver Disease
Alcohol Consumption in Diabetic Patients with Nonalcoholic Fatty Liver Disease Open
Aim . To examine the association between lifetime alcohol consumption and significant liver disease in type 2 diabetic patients with NAFLD. Methods . A cross-sectional study assessing 151 patients with NAFLD at risk of clinically significa…
View article: Multiplex Serum Protein Analysis Identifies Novel Biomarkers of Advanced Fibrosis in Patients with Chronic Liver Disease with the Potential to Improve Diagnostic Accuracy of Established Biomarkers
Multiplex Serum Protein Analysis Identifies Novel Biomarkers of Advanced Fibrosis in Patients with Chronic Liver Disease with the Potential to Improve Diagnostic Accuracy of Established Biomarkers Open
We have identified novel serum biomarkers of advanced liver fibrosis, which have the potential to enhance the diagnostic accuracy of established biomarkers. Our data suggest MMP7 is a valuable indicator of advanced fibrosis and may play a …
View article: Prevalence of medication discrepancies in patients with cirrhosis: a pilot study
Prevalence of medication discrepancies in patients with cirrhosis: a pilot study Open
There is significant discrepancy between sources of patient medication information within the hepatology clinic. Medication reconciliation and medicines-management intervention may address the complex relationship between medication discre…
View article: Altered Peripheral Blood Monocyte Phenotype and Function in Chronic Liver Disease: Implications for Hepatic Recruitment and Systemic Inflammation
Altered Peripheral Blood Monocyte Phenotype and Function in Chronic Liver Disease: Implications for Hepatic Recruitment and Systemic Inflammation Open
Chronic HCV and NAFLD differentially affect circulating monocyte phenotype, suggesting specific injury-induced signals may contribute to hepatic monocyte recruitment and systemic activation state. Monocyte function, however, was similarly …